<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">vedomostiregmed</journal-id><journal-title-group><journal-title xml:lang="ru">Регуляторные исследования и экспертиза лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Regulatory Research and Medicine Evaluation</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">3034-3062</issn><issn pub-type="epub">3034-3453</issn><publisher><publisher-name>Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">vedomostiregmed-75</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Государственная фармакопея - главный стандарт качества лекарственных средств и изделий медицинского назначения в Республике Казахстан</article-title><trans-title-group xml:lang="en"><trans-title>The State Pharmacopoeia - main standard of quality of medicines and medical devices in the Republic of Kazakhstan</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мусинов</surname><given-names>С. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Musinov</surname><given-names>S. R.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тулегенова</surname><given-names>А. У.</given-names></name><name name-style="western" xml:lang="en"><surname>Tulegenova</surname><given-names>A. U.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный центр экспертизы лекарственных средств и изделий медицинского назначения и медицинской техники</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National center of expertise of medicines, medical devices and equipment</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>13</day><month>02</month><year>2018</year></pub-date><volume>0</volume><issue>2</issue><fpage>26</fpage><lpage>30</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мусинов С.Р., Тулегенова А.У., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Мусинов С.Р., Тулегенова А.У.</copyright-holder><copyright-holder xml:lang="en">Musinov S.R., Tulegenova A.U.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.vedomostincesmp.ru/jour/article/view/75">https://www.vedomostincesmp.ru/jour/article/view/75</self-uri><abstract><p>С момента публикации первого издания Государственной фармакопеи Республики Казахстан произошли существенные изменения как в требованиях фармакопеи, так и в понимании ее роли как главного стандарта качества лекарственных средств в республике. Изменения затронули определение фармакопеи, принципы и подходы к гармонизации ее требований с основными фармакопеями мира (Европейская фармакопея, Британская фармакопея, Фармакопея США), структуру и содержание фармакопейных монографий. В статье нашли отражение такие аспекты, как миссия Государственной фармакопеи Республики Казахстан, ее место в системе стандартизации лекарственных средств и механизм функционирования, взаимосвязь требований фармакопеи с Надлежащими фармацевтическими практиками, приоритетность Государственной фармакопеи Республики Казахстан и основных фармакопей, официально признанных в республике. В связи с выходом в свет I тома второго издания Государственной фармакопеи Республики Казахстан рассмотрены статус фармакопеи и ее значимость в контексте произошедших изменений.</p></abstract><trans-abstract xml:lang="en"><p>Since the publication of the first edition of the Republic’s of Kazakhstan State Pharmacopoeia (RKSP) there have been significant changes in the requirements for the pharmacopoeia, and in the understanding of its role as the main standard of quality for medicines circulating in the country. The changes affected the Pharmacopoeia’s definition, principles of and approaches to harmonization of its requirements with the leading world pharmacopoeias (European Pharmacopoeia, British Pharmacopoeia, United States Pharmacopoeia), as well as the structure and content of pharmacopoeial monographs. The article dwells upon such aspects as the RKSP mission, its place in the drugs standardization system and functioning mechanism, the interrelation with the requirements of the good practices (GXP), ranking of the RKSP and the leading pharmacopoeias officially recognized in the country. In connection with the publication of Volume I of the RKSP 2.0 the article discusses the status of the Pharmacopoeia and its significance in the context of recent changes.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>фармакопея</kwd><kwd>гармонизация</kwd><kwd>качество лекарственного средства</kwd><kwd>общая монография</kwd><kwd>частная монография</kwd><kwd>pharmacopoeia</kwd><kwd>harmonization</kwd><kwd>quality of medicines and medical devices</kwd><kwd>general monograph</kwd><kwd>specific (individual) monograph</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Государственная фармакопея Республики Казахстан. 2-е изд. Т. I. Алматы: Жибек жолы; 2015.</mixed-citation><mixed-citation xml:lang="en">State Pharmacopoeia of the Republic of Kazakhstan. 2nd ed. V. I. Almaty: Zhibek Zholy; 2015 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">European Pharmacopoeia 8.0-8.8. Strasbourg: Council of Europe, EDQM.</mixed-citation><mixed-citation xml:lang="en">European Pharmacopoeia 8.0–8.8. Strasbourg: Council of Europe, EDQM.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">British Pharmacopoeia 2016. London: The Stationary Office on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA).</mixed-citation><mixed-citation xml:lang="en">British Pharmacopoeia 2016. London: The Stationary Office on behalf of the  Medicines and Healthcare products Regulatory Agency (MHRA).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">U. S. Pharmacopeia. National Formulary USP 38 - NF 33. Rockville: The United States Pharmacopeial Convention.</mixed-citation><mixed-citation xml:lang="en">U. S. Pharmacopeia. National Formulary USP 38—NF 33. Rockville: The United States Pharmacopeial Convention.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Государственная фармакопея Республики Казахстан. Т. I. Алматы: Жибек жолы; 2008.</mixed-citation><mixed-citation xml:lang="en">State Pharmacopoeia of the Republic of Kazakhstan. V. I. Almaty: Zhibek Zholy; 2008 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Государственная фармакопея Республики Казахстан. Т. II. Алматы: Жибек жолы; 2008.</mixed-citation><mixed-citation xml:lang="en">State Pharmacopoeia of the Republic of Kazakhstan. V. II. Almaty: Zhibek Zholy; 2008 (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Государственная фармакопея Республики Казахстан. Т. III. Алматы: Жибек жолы; 2014.</mixed-citation><mixed-citation xml:lang="en">State Pharmacopoeia of the Republic of Kazakhstan. V. III. Almaty: Zhibek Zholy; 2014 (in Russian).</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
